Wells Fargo’s Novo Nordisk NVO Stock Holding History

Wells Fargo’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-42,600	Closed	-$10K	–	7223
2020 Q4	$10K	Hold	42,600	–	–	﹤0.01%	6023
2020 Q3	$27K	Buy	+42,600	New	+$1.42M	﹤0.01%	5684
2019 Q4	–	Sell	-139,400	Closed	-$28K	–	6618
2019 Q3	$28K	Buy	+139,400	New	+$3.52M	﹤0.01%	5729

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wells Fargo's NVO Position: Q2 2026 in Review

Wells Fargo increased its Novo Nordisk (NVO) stake by 28% in Q2 2026, buying an estimated $43.6M and bringing the position to 4,657,642 shares worth $223M. The position accounts for 0.04% of the portfolio, ranked #395.

Wells Fargo first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $583M in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Wells Fargo held 4,657,642 shares of Novo Nordisk worth $223M as of Q2 2026.
Wells Fargo bought 1,015,043 Novo Nordisk shares in Q2 2026, an estimated $43.6M.
Novo Nordisk made up 0.04% of Wells Fargo's portfolio in Q2 2026, its #395 holding.
Wells Fargo first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Wells Fargo's Novo Nordisk position peaked at $583M in Q2 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.